Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk of death, major adverse cardiac events and relapse in patients with bullous pemphigoid treated with systemic or topical corticosteroids.

The British journal of dermatology·2024
Same author

Potential correlation between anti-laminin 332 autoantibodies and malignant tumours in anti-BP180-type mucous membrane pemphigoid.

Clinical and experimental dermatology·2024
Same author

Sensitive and specific assay for the serological diagnosis of anti-p200 pemphigoid based on the recombinant laminin β4 subunit.

The British journal of dermatology·2024
Same author

C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement.

Molecular therapy : the journal of the American Society of Gene Therapy·2024
Same author

Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomized controlled trial.

The British journal of dermatology·2023
Same author

The gut microbiome in bullous pemphigoid: implications of the gut-skin axis for disease susceptibility.

Frontiers in immunology·2023

Related Experiment Video

Updated: Mar 27, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.8K

Dimethylfumarate Impairs Neutrophil Functions.

Susen Müller1, Martina Behnen2, Katja Bieber1

  • 1Department of Dermatology, University of Lübeck, Lübeck, Germany.

The Journal of Investigative Dermatology
|January 15, 2016
PubMed
Summary

Dimethyl fumarate (DMF) inhibits neutrophil activation, impacting key functions like migration and extracellular trap formation. This research suggests DMF

More Related Videos

Author Spotlight: Balancing Speed, Cost, and Accuracy in Neutrophil Function Assessment with NeutroFun Screen Protocol
12:27

Author Spotlight: Balancing Speed, Cost, and Accuracy in Neutrophil Function Assessment with NeutroFun Screen Protocol

Published on: February 9, 2024

4.0K
Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

10.8K

Related Experiment Videos

Last Updated: Mar 27, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.8K
Author Spotlight: Balancing Speed, Cost, and Accuracy in Neutrophil Function Assessment with NeutroFun Screen Protocol
12:27

Author Spotlight: Balancing Speed, Cost, and Accuracy in Neutrophil Function Assessment with NeutroFun Screen Protocol

Published on: February 9, 2024

4.0K
Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

10.8K

Area of Science:

  • Immunology
  • Cell Biology
  • Pharmacology

Background:

  • Neutrophil activation is crucial for host defense but implicated in chronic inflammatory diseases.
  • Fumarates are known to treat conditions like psoriasis and multiple sclerosis, with effects previously attributed to lymphocytes and dendritic cells.
  • The specific role of dimethyl fumarate (DMF) in modulating neutrophil function remained largely unexplored.

Purpose of the Study:

  • To investigate the effects of dimethyl fumarate (DMF) on neutrophil activation and function.
  • To elucidate the underlying molecular mechanisms of DMF's action on neutrophils.
  • To validate the therapeutic potential of DMF in preclinical models of neutrophil-mediated diseases.

Main Methods:

  • In vitro assessment of DMF's impact on neutrophil activation markers, reactive oxygen species production, neutrophil extracellular trap formation, and migration.
  • Ex vivo evaluation of phagocytic capacity and autoantibody-induced tissue injury.
  • Analysis of DMF's modulation of key signaling pathways, including PI3K/Akt and MAPK pathways.
  • In vivo studies using mouse models of epidermolysis bullosa acquisita to assess DMF's efficacy in preventing and treating disease manifestations.

Main Results:

  • Dimethyl fumarate (DMF) significantly inhibited neutrophil activation in vitro, including surface marker expression, ROS production, NET formation, and migration.
  • DMF impaired phagocytic ability and reduced autoantibody-induced, neutrophil-dependent tissue injury ex vivo.
  • DMF modulated neutrophil activation pathways in a stimulus-dependent manner.
  • In vivo, DMF treatment significantly reduced blistering in a mouse model of epidermolysis bullosa acquisita and improved established disease.

Conclusions:

  • Dimethyl fumarate (DMF) exhibits potent inhibitory effects on diverse neutrophil functions.
  • DMF targets key signaling pathways involved in neutrophil activation.
  • These findings support the potential application of DMF in treating neutrophil-mediated inflammatory and autoimmune diseases.